Treatment of heart failure with normal ejection fraction

被引：5

作者：

Hamdani N. ^{[1
]}

Paulus W.J. ^{[1
]}

机构：

[1] Laboratory for Physiology, VU University Medical Center, Amsterdam 1081 BT

来源：

Current Treatment Options in Cardiovascular Medicine | 2011年 / 13卷 / 1期

关键词：

Left Ventricular Hypertrophy; Heart Failure Patient; Candesartan; Perindopril; Ivabradine;

D O I：

10.1007/s11936-010-0103-8

中图分类号：

学科分类号：

摘要：

Opinion Statement: Heart failure (HF) is a major cause of mortality and morbidity and one of the most frequent reasons for hospital admission in the United States and Europe. Currently, more than 50% of HF patients have a normal (N) left ventricular (LV) ejection fraction (EF) (LVEF >50%). The main pathophysiologic processes involved in HFNEF are increased LV stiffness and abnormal relaxation, resulting in impaired LV filling. Hypertension and myocardial ischemia are the most common causes of HFNEF. Precipitating factors include volume overload, tachycardia, physical exercise, systemic stressors (such as fever and infection), arrhythmia, increased salt intake, and use of nonsteroidal anti-inflammatory drugs. There is little evidence to guide treatment, as previously HFNEF patients have been excluded from clinical trials on the basis of a normal LVEF. Survival improved over time in patients with reduced (R) EF (HFREF) (LVEF <40%), reflecting the beneficial effects of treatment in this phenotype. However, survival did not improve for HFNEF patients. The approach to the treatment of HFNEF patients should focus on reducing LV filling pressure, controlling hypertension, modifying ischemia, and improving LV relaxation. Therefore, diuretics are suitable for HFNEF patients to reduce ventricular filling pressure. Hypertension can be treated by using multiple agents if necessary. Drugs of particular interest and recommended to treat hypertension are calcium channel blockers (CCBs) and antagonists of the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and aldosterone antagonists. Ischemic heart disease can be treated with antiplatelet therapy, anticoagulants, and β-blockers. Heart rate control in atrial fibrillation can be achieved with β-blockers and digoxin. Finally, ACE inhibitors and ARBs could potentially decrease LV hypertrophy in hypertensive patients with HFNEF. © 2010 The Author(s).

引用

页码：26 / 34

页数：8

共 40 条

[1]

Bursi F., Weston S.A., Redfield M.M., Jacobsen S.J., Pakhomov S., Nkomo V.T., Meverden R.A., Roger V.L., Systolic and diastolic heart failure in the community, Journal of the American Medical Association, 296, 18, pp. 2209-2216, (2006)

[2]

Brucks S., Little W.C., Chao T., Kitzman D.W., Wesley-Farrington D., Gandhi S., Shihabi Z.K., Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction, American Journal of Cardiology, 95, 5, pp. 603-606, (2005)

[3]

Kitzman D.W., Little W.C., Brubaker P.H., Anderson R.T., Gregory Hundley W., Marburger C.T., Brosnihan B., Morgan T.M., Stewart K.P., Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure, Journal of the American Medical Association, 288, 17, pp. 2144-2150, (2002)

[4]

Zile M.R., Gaasch W.H., Carroll J.D., Et al., Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?, Circulation, 104, pp. 779-782, (2001)

[5]

Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G., Leite-Moreira A.F., Borbely A., Edes I., Handoko M.L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A.G., Brutsaert D.L., How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

[6]

Dickstein K., Cohen-Solal A., Filippatos G., Et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur J Heart Fail, 10, pp. 933-989, (2008)

[7]

Hunt S.A., Baker D.W., Chin M.H., Et al., ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), Circulation, 104, pp. 2996-3007, (2001)

[8]

Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., Noble R.Joseph, Packer M., Silver M.A., Stevenson L.W., Gibbons R.J., Antman E.M., Alpert J.S., Faxon D.P., Fuster V., Gregoratos G., Jacobs A.K., Hiratzka L.F., Russell R.O., Smith Jr. S.C., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Hear

[9]

Massie B.M., Carson P.E., McMurray J.J., Et al., Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, pp. 2456-2467, (2008)

[10]

Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, European Heart Journal, 27, 19, pp. 2338-2345, (2006)

← 1 2 3 4 →